ACTRN12621000034831已完成1 期
Virucidal pilot study of Nasodine® (povidone-iodine 0.5%) nasal spray in people in South Africa with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus.
Firebrick Pharma Limited0 个研究点目标入组 23 人开始时间: 2021年1月15日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 23
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Prevention
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •Adult (18+ years old) patients with
- •(a) confirmed COVID-19 symptoms and
- •(b) symptom onset within the past five days.
排除标准
- •Known iodine sensitivity
- •Previously diagnosed thyroid disease
- •Previously diagnosed kidney disease
- •Known to be pregnant or currently breastfeeding
研究者
相似试验
撤回
1 期
Virucidal pilot study of Nasodine® Antiseptic Nasal Spray (povidone-iodine 0.5%) in people with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus.COVID-19 PositiveInfection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12620000470998Firebrick Pharma Pty Ltd20
进行中（未招募）
不适用
A pilot study of the ability of povidone-iodine (PVP-I) 0.5% aqueous solution oral/nasal spray and mouthwash to kill the SARS-CoV-2 virus in people with COVID-19ISRCTN13447477Royal Surrey County Hospital NHS Foundation Trust22
Unknown
4 期
Halodine Nasal Antiseptic in Patients With COVID-19SARS-CoV-2 InfectionNCT04517188Halodine LLC40
Unknown
1 期
Phase I/II Trial of Povidone-iodine (PVP-I) Nasal Swab For Preventing COVID-19 Spread in Healthy SubjectsCovid19Povidone Iodine Adverse ReactionNCT04510402Brigham and Women's Hospital50
已完成
2 期
A controlled trial of topical Povidone-iodine to treat EKCEpidemic Keratoconjunctivitis.Superficial keratitis with conjunctivitisIRCT2015021518004N2Vice chancellor for research, Zahedan University of Medical Sciences60